Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,

Published bySheryl West Modified over 8 years ago

Similar presentations

Presentation on theme: "Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,"— Presentation transcript:

1 Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett, R.N., M.A.; Frederic S. Resnic, M.D., M.Sc.; and Sharon-Lise T. Normand, Ph.D. Brigham and Women’s Hospital, Harvard Medical School, Harvard School of Public Health Boston, Massachusetts Study funding from Massachusetts Department of Public Health November 4, 2007 American Heart Association Scientific Sessions

2 Drug-Eluting and Bare Metal Stenting in Massachusetts Background The data reported for available DES in the US indicate that these devices are important advancements by reducing the need for revascularization Long term clinical outcomes remain uncertain following DES use compared to BMS use in the general population

3 Drug-Eluting and Bare Metal Stenting in Massachusetts Background Randomized trials of DES have been limited in power to detect rare events and in generalizability to a broad range of practice patterns and patient populations Observational studies have been limited by possible residual selection bias and incomplete follow-up Studies comparing DES and BMS use have been performed in populations with restricted DES use

4 Drug-Eluting and Bare Metal Stenting in Massachusetts Objectives – To evaluate whether the use of DES is associated with increased rates of death or MI compared with BMS in general use representative of current US practice – To confirm whether the use of DES is associated with reduction in revascularization compared with BMS in general use representative of current US practice

5 Drug-Eluting and Bare Metal Stenting in Massachusetts Methods: Data source Mass-DAC All PCI in Massachusetts (>25000 stent procedures per year) Massachusetts Dept. of Public Health mandatory reporting Clinical and procedural factors collected prospectively using ACC NCDR instrument Mortality from hospital record, Mass. vital statistics and Social Security website Myocardial infarction and revascularization from Mass-DAC PCI and CABG data merged with hospital discharge data Index procedures performed April 2003 – September 2004 Non-Massachusetts residents excluded

6 Drug-Eluting and Bare Metal Stenting in Massachusetts Methods: Propensity Score Matched Analysis Patients assigned to DES or BMS groups based on treatment at index procedure Propensity score matching – Logistic regression to predict DES treatment by patient, procedural, hospital variables – Caliper matching of DES to BMS patients Primary outcomes: Matched risk differences for mortality, myocardial infarction and revascularization rates at 2 years Paired t-test, 2-sided alpha 0.05

7 Drug-Eluting and Bare Metal Stenting in Massachusetts 7 N=21,019 PCI Patients in Massachusetts April 1, 2003- September 30, 2004 Complete 2 year follow-up N=21,019 PCI Patients in Massachusetts April 1, 2003- September 30, 2004 Complete 2 year follow-up 1,538 non-residents excluded 564 adminstrative files not linkable N=18,917 PCI Patients N=18,917 N=11,516 DES Only Patients N=11,516 N=6,210 BMS Only Patients N=6,210 1,191 patients with both stent types excluded

8 35% BMS 65% DES 72% sirolimus, 28% paclitaxel eluting stents

9 Drug-Eluting and Bare Metal Stenting in Massachusetts Patient Characteristics before Match DES (n = 11516) BMS (n =6210) p value Age – yrs 64.4 ±12.3 65.3 ±13.0 <0.001 Female (%) 32.032.20.85 Diabetes Mellitus (%) 28.927.40.04 Insulin Dependent Diabetes Insulin Dependent Diabetes9.78.80.07 Hyperlipidemia (%) 77.171.9<0.001 Hypertension (%) 76.172.6<0.001 Current Smoker (%) 19.623.2<0.001 Prior PCI (%) 22.520.70.004 Prior MI (%) 26.928.70.01 Prior CABG (%) 13.016.1<0.001

10 Drug-Eluting and Bare Metal Stenting in Massachusetts Patient Characteristics before Match DES (n = 11516) BMS (n =6210) p value Congestive Heart Failure (%) 9.812.2<0.001 Chronic Lung Disease (%) 10.812.20.003 History of Neoplasm (%) 2.13.2<0.001 History of GI Bleeding (%) 1.62.4<0.001 Chronic Renal Insufficiency (%) 6.27.00.03 Dialysis (%) 1.51.70.10 Clopidogrel Pretreatment (%) 34.833.70.13 GpIIbIIIa Inhibitor Pretreatment (%) 16.223.5<0.001

11 Drug-Eluting and Bare Metal Stenting in Massachusetts Procedure Indications before Match DES (n = 11516) BMS (n =6210) p value Procedure status <0.001 Urgent (%) Urgent (%)39.736.3 Emergency/Salvage (%) Emergency/Salvage (%)13.828.9 Indication Non-ST elevation MI (%) Non-ST elevation MI (%)20.821.70.14 ST elevation MI (%) ST elevation MI (%)13.529.2<0.001 Treatment for restenosis 7.13.9<0.001 Atheroablative therapy 5.34.40.012 Thrombectomy3.17.7<0.001 Brachytherapy0.40.40.81

12 Drug-Eluting and Bare Metal Stenting in Massachusetts Procedural Characteristics before Match DES (n = 11516) BMS (n =6210) p value Number of vessels treated 1.19 ± 0.43 1.13 ± 0.36 <0.001 Number of lesions treated 1.44 ± 0.72 1.36 ± 0.67 <0.001 Left anterior descending (%) Left anterior descending (%)45.638.7<0.001 Circumflex (%) Circumflex (%)32.529.9<0.001 Right coronary (%) Right coronary (%)38.342.5<0.001 Left main (%) Left main (%)1.81.90.65 Saphenous vein graft (%) Saphenous vein graft (%)4.49.1<0.001 Arterial graft (%) Arterial graft (%)0.40.40.48

13 Drug-Eluting and Bare Metal Stenting in Massachusetts, Unadjusted 2-Year Outcomes BMS(n=768/6210)DES(n=769/11516) 12.4% 6.7% Mortality P < 0.0001 RevascularizationDES(n=2297/11516)BMS(n=1488/6210) P < 0.0001 24.0% 20.0% MIDES(n=1049/11516)BMS(n=754/6210) P < 0.0001 12.1% 9.1 %

14 n=5441 DES n=5441 BMS Propensity matched pairs 63 variables

15 Drug-Eluting and Bare Metal Stenting in Massachusetts Patient Characteristics after Match DES (n = 5441) BMS (n =5441) % SD Age – yrs 66.265.30.07 Female (%) 33.332.32.27 Diabetes Mellitus (%) 27.328.1-1.85 Hyperlipidemia (%) 69.873.3-7.71 Hypertension (%) 72.473.8-3.23 Current Smoker (%) 23.722.23.41 Prior PCI (%) 20.621.1-1.40 Prior MI (%) 30.928.45.51 Prior CABG (%) 16.415.33.17 *%SD = Percent Standardized Difference Values <10% reflect well-matched characteristics

16 Drug-Eluting and Bare Metal Stenting in Massachusetts Patient Characteristics after Match DES (n = 5441) BMS (n =5441) %SD Congestive Heart Failure (NYHA 3-4) 8.56.86.29 Chronic Lung Disease (%) 14.012.35.06 History of Neoplasm (%) 3.82.95.02 History of GI Bleeding (%) 2.52.12.96 Chronic Renal Insufficiency (%) 7.66.92.76 Dialysis (%) 1.81.71.13 Clopidogrel Preadminstered (%) 35.934.13.74 GpIIbIIIa Inhibitor Preadminstered (%) 25.021.97.42 *%SD = Percent Standardized Difference Values <10% reflect well-matched characteristics

17 Drug-Eluting and Bare Metal Stenting in Massachusetts Procedure Characteristics after Match DES (n = 5441) BMS (n =5441) %SD Procedure status Urgent (%) Urgent (%)37.138.2-2.28 Emergency/Salvage (%) Emergency/Salvage (%)27.923.410.28 Indication Non-ST elevation MI (%) Non-ST elevation MI (%)24.522.93.63 ST elevation MI (%) ST elevation MI (%)26.623.46.30 Treatment for restenosis 3.04.3-6.89 Atheroablative therapy 5.14.71.88 Thrombectomy6.35.62.79 Brachytherapy0.50.40.45 *%SD = Percent Standardized Difference Values <10% reflect well-matched characteristics

18 Drug-Eluting and Bare Metal Stenting in Massachusetts Procedural Characteristics after Match DES (n = 5441) BMS (n =5441) %SD Multilesion treatment 2 lesions 2 lesions21.922.6-1.63 3 lesions 3 lesions4.65.4-3.89 4 lesions 4 lesions1.21.20.17 Target vessel Target vessel Left circumflex Left circumflex29.731.0-2.80 Right coronary Right coronary43.540.95.36 Left main Left main2.22.01.53 Saphenous vein graft Saphenous vein graft8.87.54.64 Arterial graft Arterial graft0.30.4-1.25 *%SD = Percent Standardized Difference Values <10% reflect well-matched characteristics

19 Drug-Eluting and Bare Metal Stenting in Massachusetts, Primary Results Propensity Matched 2-Year Outcomes BMS(n=647/5441)DES(n=514/5441) 11.9% 9.4% Mortality P < 0.0001 RevascularizationDES(n=1095/5441) BMS(n=1303/5441) P < 0.0001 23.9% 20.1% MIDES(n=590/5441)BMS(n=643/5441) P = 0.11 11.8% 10.8%  = -3.8% [-5.4,-2.3]  = -1.0% [-2.2,+0.2]  = -2.4% [-3.6,-1.3]

20 Cumulative Incidence 10% 20% 30% 0 0% 180365730 (At risk) Days 0180365730 DES5,4415,3385,2195,123 BMS5,4415,2795,1054,995 DES n=5,441 BMS n=5,441 Time after Initial Procedure (days) 11.9% 9.4% Drug-Eluting and Bare Metal Stenting in Massachusetts 2-Year Outcome in Matched Patients Mortality

21 (At risk) Days 0180365730 DES5,4415,1034,8964,729 BMS5,4415,0294,7474,569 DES n=5,441 BMS n=5,441 Time after Initial Procedure (days) 12.3% 11.2% Drug-Eluting and Bare Metal Stenting in Massachusetts 2-Year Outcome in Matched Patients MI Cumulative Incidence 10% 20% 30% 0 0% 180365730

22 (At risk) Days 0180365730 DES5,4414,9404,5814,309 BMS5,4414,9094,3033,992 DES n=5,441 BMS n=5,441 Time after Initial Procedure (days) 25.1% 20.9% Drug-Eluting and Bare Metal Stenting in Massachusetts 2-Year Outcome in Matched Patients Revascularization Cumulative Incidence 10% 20% 30% 0 0% 180365730

23 Drug-Eluting and Bare Metal Stenting in Massachusetts Matched Risk Differences at 2 years Myocardial Infarction DES10.8% BMS11.3% Mortality DES 9.4% BMS11.9% Revascularization DES20.1% BMS23.9% Favors DES Favors BMS Risk Difference (95% CI) -5%0 5%  = -2.4% [-3.6,-1.3] p<0.0001  = -1.0% [-2.2,+0.2] p=0.11  = -3.8% [-5.4,-2.3] p<0.0001

24 Drug-Eluting and Bare Metal Stenting in Massachusetts Sensitivity analyses Effect of differential rates of use of DES vs BMS over time 2 day mortality difference

25 n=3752 DES n=3752 BMS Propensity matched pairs adjusted for time on market

26 Drug-Eluting and Bare Metal Stenting in Massachusetts Sensitivity Analysis 2-Year Outcomes adjusted for time on market BMS(n=439/3752)DES(n=318/3752) 11.7% 8.5% Mortality P < 0.0001 RevascularizationDES(n=784/3752)BMS(n=858/3752) P = 0.040 22.9% 20.9% MIDES(n=370/3752)BMS(n=422/3752) P = 0.052 11.8% 10.8%  = -1.9% [-3.9,-0.1]  = -1.4% [-2.8,0.0]  = -3.2% [-4.6,-1.8]

27 Drug-Eluting and Bare Metal Stenting in Massachusetts Sensitivity analyses Adjustment for time on market is consistent with results of the primary analysis – larger observed difference favoring DES for mortality 2 day mortality difference after propensity match is small 2 day mortality 0.4% vs 0.8% (DES vs BMS)  = -0.4% at 2d vs  = -2.4% at 2 y

28 Drug-Eluting and Bare Metal Stenting in Massachusetts Comparison with PCI Practice Patterns and Other Studies Adult population DES patients BMS patients DES(%)Studyduration Sweden 1 9 million 603313738301/03-12/04 Western Denmark 2 3 million 35488847291/02-6/05 Ontario 3 9 million 510682473812/03-3/05 Massachusetts 6 million 115166210654/03-9/04 Distinguishing features: high rate of PCI/population, high rate of DES/procedure, study sample chosen to start with introduction of DES and to end when all patients had complete 2 year follow up. 1. Lagerqvist B et al. N Engl J Med 2007;356:1009-19. 2. 1. Lagerqvist B et al. N Engl J Med 2007;356:1009-19. 2. Jensen, LO et al. JACC 2007;50(5):463- 70. 3. Tu J et al. NEJM 2007;357:1393-42.

29 From the Massachusetts state dataset of 21,024 PCI unique patient procedures in Massachusetts from April 2003- September 2004 with complete 2y follow-up, propensity matched analysis of 10,882 patients demonstrated: No increase in rates of death, or myocardial infarction associated with DES as compared to BMS use at 2 years. – A significantly lower mortality rate was observed for DES at 2 years, and will be monitored as follow up proceeds to 3-5 years A lower rate of revascularization in patients treated with DES compared with BMS. Drug-Eluting and Bare Metal Stenting in Massachusetts Conclusions

Download ppt "Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,"

Similar presentations

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.

Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.

PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst M.D Ph.D;

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst M.D Ph.D;
Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.

Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.
Can we prevent stent restenosis after coronary stent implantation

Can we prevent stent restenosis after coronary stent implantation
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.

J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention JA Rassen, MA Mittleman, RJ Glynn, A.

Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention JA Rassen, MA Mittleman, RJ Glynn, A.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.

Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,

Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.

Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.

1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

Similar presentations

Ads by Google